Amid disruption in Ukraine, international partnerships are preserving oncology progress—and building the foundation for long-term recovery.
Although liver cancer isn’t as prevalent as lung cancer or breast cancer, this cancer is now the fastest-increasing cause...
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the...
While immunotherapy may be the latest tool in the treatment armamentarium for cancer, many ongoing clinical trials are assessing...
Norman E. “Ned” Sharpless, MD, who became director of the National Cancer Institute in October 2017, recently unveiled areas...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
This was another spectacular year for the AACR Annual Meeting with its record-breaking attendance of more than 22,500. From...
The AACR Annual Meeting 2018 drew more than 22,600 people to Chicago, providing a front-row seat to some exciting...
A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted...
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients...
This post originally appeared on the Cancer Today website. Roads and roadblocks, both literal and metaphorical, figured into a...